Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stemcentrx, Inc.

http://www.stemcentrx.com/

Latest From Stemcentrx, Inc.

Stockwatch: Repeating Past Mistakes At AbbVie

AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.

M & A Stockwatch

AbbVie Puts Final Nail In Rova-T's Coffin After Another Trial Failure

AbbVie already wrote off $4bn of the $5.8bn Stemcentrx acquisition that gave it the antibody-drug-conjugate, but now the company has ended all Rova-T development.

Clinical Trials Cancer

AbbVie Will Use Allergan Revenue To Fund Combined Firm's Large R&D Pipeline

While AbbVie said its $63bn purchase places little value on Allergan's R&D pipeline, the companies have 62 drugs in clinical development with 38 in Phase II and III or filed with regulators, including new indications for approved products.

Deals Business Strategies

AbbVie’s Downward Humira Guidance Worries Analysts

Decreasing Humira’s ex-US sales guidance for the second time in three months caught significant attention, as AbbVie now expects 30% revenue erosion for its top-seller outside its home market.

Sales & Earnings Commercial
See All

Company Information

UsernamePublicRestriction

Register